Online inquiry

IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1165MR)

This product GTTS-WQ1165MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1165MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15336MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ12023MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ974MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ9349MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ1386MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ8047MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ7564MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ2656MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 655
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW